Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219693 · ClinicalTrials.gov registry record
QuantaFlo HD Clinical Validation Study
A clinical trial of To Assess Cardiovascular Function, sponsored by Semler Scientific.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT07219693 is a study of To Assess Cardiovascular Function that is actively recruiting participants, run by Semler Scientific. The registered enrollment target is 600 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07219693, a study of To Assess Cardiovascular Function, is actively recruiting participants, sponsored by Semler Scientific.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
Conditions Studied
Interventions
- DEVICE QuantaFlo HD
Study Locations (1)
Arizona
- Pima Heart and Vascular - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219693
The ClinicalTrials.gov registry entry for NCT07219693 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Semler Scientific, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with To Assess Cardiovascular Function appearing as the primary indexed condition, and to 1 intervention - of which QuantaFlo HD is the first listed.
NCT07219693 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07219693 about?
NCT07219693 is a clinical study titled "QuantaFlo HD Clinical Validation Study". The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater th...
What is the current status of trial NCT07219693?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-08-21. Estimated completion is 2026-06-30.
What conditions does trial NCT07219693 study?
This clinical trial studies the following conditions: To Assess Cardiovascular Function.
What interventions are being tested in trial NCT07219693?
The interventions under investigation include: QuantaFlo HD (DEVICE).
Who is sponsoring clinical trial NCT07219693?
This trial is sponsored by Semler Scientific, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219693 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.